Bolt Biotherapeutics (BOLT) Fundamental Analysis: Revenue, Earnings & Valuation

1.09 / 10

Underperform

Fundamental assessment rates the company as Underperform with a 1.1/10 score. Positive points include accounts‑receivable and fixed‑asset turnover, but revenue growth is flat and the income‑tax‑to‑profit ratio is high, leading to a weak overall financial outlook.

Analysis Checks(5/10)

Revenue-MV

Value-2.72

Score1/3

Weight38.27%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value0.07

Score1/3

Weight-8.80%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-4.10%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-4.06%

1M Return-0.65%

PB-ROE

Value2.63

Score1/3

Weight38.29%

1M Return5.22%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-9.23%

1M Return-1.54%

Fixed assets turnover ratio

Value0.34

Score2/3

Weight-6.48%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.58%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-4.50%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight65.18%

1M Return7.28%

Is BOLT fundamentally strong?

BOLT scores 1.09/10 on fundamentals and holds a Premium valuation at present. Backed by its -79.75% ROE, -433.74% net margin, -0.25 P/E ratio, 0.32 P/B ratio, and 46.01% earnings growth, these metrics solidify its Underperform investment rating.